We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01025934
First Posted: December 4, 2009
Last Update Posted: December 4, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Napoli CTO Hospital
Information provided by:
University of Campania "Luigi Vanvitelli"
December 3, 2009
December 4, 2009
December 4, 2009
Not Provided
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy
Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy
The purpose of this study is to evaluate the role, the safety and the effectiveness of Intravitreal Bevacizumab injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy.
Not Provided
Interventional
Phase 4
Primary Purpose: Treatment
Proliferative Diabetic Retinopathy
  • Drug: Bevacizumab
  • Other: sham
  • Active Comparator: 7 days
    Intervention: Drug: Bevacizumab
  • Active Comparator: 20 days
    Intervention: Drug: Bevacizumab
  • Sham Comparator: sham
    Intervention: Other: sham
di Lauro R, De Ruggiero P, di Lauro R, di Lauro MT, Romano MR. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010 Jun;248(6):785-91. doi: 10.1007/s00417-010-1303-3. Epub 2010 Feb 5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • vitreous haemorrhage
  • tractional retinal detachment
  • active proliferative diabetic retinopathy.

Exclusion Criteria:

  • neovascular glaucoma
  • cataract
  • combined traction and rhegmatogenous RD
Sexes Eligible for Study: All
Child, Adult, Senior
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01025934
IVBDRNA
No
Not Provided
Not Provided
Not Provided
University of Campania "Luigi Vanvitelli"
Napoli CTO Hospital
Not Provided
University of Campania "Luigi Vanvitelli"
December 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP